Study Details

Single-agent Erlotinib in patients previously treated with oral etoposide in protocol OSI-774-205

The study has stopped early and will not start again. Participants were not enrolled (for withdrawn studies), however if participants were enrolled, they are no longer being examined or treated. ID

The unique identification code given to each clinical study upon registration at

Astellas Study ID

The unique identification code given by the study sponsor.


EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).





These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2


1 years - 21 years


Female & Male




A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


Trial Dates

May 2011 - Sep 2012


None (Open Label)

Enrollment number


Open-label Phase 2 Study of Single-agent Erlotinib for Patients with Pediatric Ependymoma Previously Treated with Oral Etoposide in Protocol OSI-774-205

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Single-agent Erlotinib in patients previously treated with oral etoposide in protocol OSI-774-205? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.


Hospital for Sick Children

Toronto, Canada, M5G 1X8

Children's National Medical Center -D.C. Center for Cancer and Blood Disorders

Washington, United States, 20010

Royal Marsden Hospital

Sutton, United Kingdom, SM2 5pt

Oregon Health & Sciences University Doernbecher Children's Hospital

Portland, United States, 97124

Stollery Children's Hospital

Edmonton, Canada, T6G 2B7

University of Minnesota - Amplatz Children's Hospital

Minneapolis, United States, 55455

University of Alabama at Birmingham

Birmingham, United States, 35233

Packard Children's Hospital

Palo Alto, United States, 94304

Children's Memorial Medical Hospital

Chicago, United States, 60614

Children's Hospital of Orange County (CHOC)

Orange, United States, 92868

University of Nottingham

Nottingham, United Kingdom, NG7 2UH

University of Miami

Miami, United States, 33136

Childrens Hospital of Pittsburgh of UPMC

Pittsburgh, United States, 15224

Children's and Women's Health Center of BC

Vancouver, Canada, V6H 3V4

The Children's Hospital Center for Cancer and Blood Disorders

Aurora, United States, 80045

Royal Manchester Children's Hospital Ward 84

Manchester, United Kingdom, M13 9W2

Emory University Children's Healthcare of Atlanta

Atlanta, United States, 30322

Paediatric Oncology and Haematology Offices,

Leeds, United Kingdom, LS1 3EX

Royal Hospital for Sick Children

Glasgow, United Kingdom, G3 8SJ

Birmingham Children’s Hospital Oncology Department

Birmingham, United Kingdom, B4 6NH

Alder Hey Children's NHS Foundation Trust

Liverpool, United Kingdom, L12 1AP

University of Wisconsin

Madison, United States, 53705-2275